000009877 001__ 9877
000009877 005__ 20200402205835.0
000009877 0247_ $$2pmid$$apmid:19954333
000009877 0247_ $$2DOI$$a10.1089/rej.2009.0924
000009877 0247_ $$2WOS$$aWOS:000277602200017
000009877 0247_ $$2altmetric$$aaltmetric:21804052
000009877 037__ $$aPreJuSER-9877
000009877 041__ $$aeng
000009877 082__ $$a610
000009877 084__ $$2WoS$$aGeriatrics & Gerontology
000009877 1001_ $$0P:(DE-Juel1)VDB65461$$aBartnik, D.$$b0$$uFZJ
000009877 245__ $$aDifferently Selected D-Enantiomeric Peptides Act on Different A beta Species
000009877 260__ $$aLarchmont, NY$$bLiebert$$c2010
000009877 300__ $$a
000009877 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000009877 3367_ $$2DataCite$$aOutput Types/Journal article
000009877 3367_ $$00$$2EndNote$$aJournal Article
000009877 3367_ $$2BibTeX$$aARTICLE
000009877 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000009877 3367_ $$2DRIVER$$aarticle
000009877 440_0 $$018202$$aRejuvenation Research$$v13$$x1549-1684$$y2
000009877 500__ $$aRecord converted from VDB: 12.11.2012
000009877 520__ $$aAging is the most significant risk factor for Alzheimer disease (AD). The pathological hallmark of AD is the accumulation of aggregated amyloid-beta (Abeta) forms and insoluble plaques, mainly composed of Abeta, in the brain of the patient. Recently, we reported on the selection of D-enantiomeric, Abeta-binding peptides D1 and D3. D1 was selected against aggregated Abeta species to address diagnosis by in vivo imaging of amyloid plaques, whereas D3 was selected using low-molecular-weight Abeta species, therefore addressing therapeutical studies. Here, we use a surface plasmon resonance method to confirm that both peptides show the desired binding specificities.
000009877 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems$$cP33$$x0
000009877 536__ $$0G:(DE-Juel1)FUEK505$$aBioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung$$cP45$$x1
000009877 588__ $$aDataset connected to Web of Science, Pubmed
000009877 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000009877 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000009877 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000009877 650_2 $$2MeSH$$aAmyloid: analysis
000009877 650_2 $$2MeSH$$aAmyloid: chemistry
000009877 650_2 $$2MeSH$$aAmyloid beta-Peptides: chemistry
000009877 650_2 $$2MeSH$$aAmyloid beta-Peptides: drug effects
000009877 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000009877 650_2 $$2MeSH$$aHumans
000009877 650_2 $$2MeSH$$aOligopeptides: chemistry
000009877 650_2 $$2MeSH$$aOligopeptides: metabolism
000009877 650_2 $$2MeSH$$aOligopeptides: pharmacology
000009877 650_2 $$2MeSH$$aPeptide Fragments: chemistry
000009877 650_2 $$2MeSH$$aPeptide Fragments: isolation & purification
000009877 650_2 $$2MeSH$$aPeptide Fragments: metabolism
000009877 650_2 $$2MeSH$$aPeptide Fragments: pharmacology
000009877 650_2 $$2MeSH$$aPlaque, Amyloid: chemistry
000009877 650_2 $$2MeSH$$aPlaque, Amyloid: drug effects
000009877 650_2 $$2MeSH$$aPlaque, Amyloid: metabolism
000009877 650_2 $$2MeSH$$aProtein Binding
000009877 650_2 $$2MeSH$$aProtein Isoforms: analysis
000009877 650_2 $$2MeSH$$aProtein Isoforms: chemistry
000009877 650_2 $$2MeSH$$aProtein Multimerization: drug effects
000009877 650_2 $$2MeSH$$aSubstrate Specificity
000009877 650_2 $$2MeSH$$aSurface Plasmon Resonance
000009877 650_7 $$00$$2NLM Chemicals$$aAmyloid
000009877 650_7 $$00$$2NLM Chemicals$$aAmyloid beta-Peptides
000009877 650_7 $$00$$2NLM Chemicals$$aD3 peptide
000009877 650_7 $$00$$2NLM Chemicals$$aOligopeptides
000009877 650_7 $$00$$2NLM Chemicals$$aPeptide Fragments
000009877 650_7 $$00$$2NLM Chemicals$$aProtein Isoforms
000009877 650_7 $$2WoSType$$aJ
000009877 7001_ $$0P:(DE-Juel1)VDB65869$$aFunke, S. A.$$b1$$uFZJ
000009877 7001_ $$0P:(DE-HGF)0$$aAndrei-Selmer, L.C.$$b2
000009877 7001_ $$0P:(DE-HGF)0$$aBacher, M.$$b3
000009877 7001_ $$0P:(DE-HGF)0$$aDodel, R.$$b4
000009877 7001_ $$0P:(DE-Juel1)132029$$aWillbold, D.$$b5$$uFZJ
000009877 773__ $$0PERI:(DE-600)2155984-3$$a10.1089/rej.2009.0924$$gVol. 13$$q13$$tRejuvenation research$$v13$$x1549-1684$$y2010
000009877 909CO $$ooai:juser.fz-juelich.de:9877$$pVDB
000009877 9131_ $$0G:(DE-Juel1)FUEK409$$bGesundheit$$kP33$$lFunktion und Dysfunktion des Nervensystems$$vFunktion und Dysfunktion des Nervensystems$$x0
000009877 9131_ $$0G:(DE-Juel1)FUEK505$$bSchlüsseltechnologien$$kP45$$lBiologische Informationsverarbeitung$$vBioSoft: Makromolekulare Systeme und biologische Informationsverarbeitung$$x1
000009877 9132_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lBioSoft  Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000009877 9141_ $$y2010
000009877 915__ $$0StatID:(DE-HGF)0010$$aJCR/ISI refereed
000009877 9201_ $$0I:(DE-Juel1)VDB942$$d31.12.2010$$gISB$$kISB-3$$lStrukturbiochemie$$x0
000009877 9201_ $$0I:(DE-82)080012_20140620$$gJARA$$kJARA-HPC$$lJülich Aachen Research Alliance - High-Performance Computing$$x1
000009877 970__ $$aVDB:(DE-Juel1)119984
000009877 980__ $$aVDB
000009877 980__ $$aConvertedRecord
000009877 980__ $$ajournal
000009877 980__ $$aI:(DE-Juel1)ICS-6-20110106
000009877 980__ $$aI:(DE-82)080012_20140620
000009877 980__ $$aUNRESTRICTED
000009877 981__ $$aI:(DE-Juel1)IBI-7-20200312
000009877 981__ $$aI:(DE-Juel1)ICS-6-20110106
000009877 981__ $$aI:(DE-Juel1)VDB1346